blog
Last updated: 2024-12-20

(Bladder Cancer) Immune Clinical Trial Enrollment

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
(Bladder Cancer) Immune Clinical Trial Enrollment

(Bladder Cancer) Immune Clinical Trial Enrollment

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

A clinical trial is evaluating the feasibility of a new preoperative immunotherapy approach for bladder cancer patients: combining the PD-1 inhibitor Opdivo (nivolumab) with the CTLA-4 inhibitor Yervoy (ipilimumab). Cancer treatment has evolved rapidly in recent years. Beyond traditional surgery, radiation, and chemotherapy, targeted therapies have flourished over the past two decades. With advances in medical research, scientists have uncovered the complex interactions between the human immune system and tumor cells, driving the rise of immunotherapy as another important milestone in cancer treatment.

The following eligibility criteria apply for inquiries about this clinical trial.

The trial procedure is outlined below.

Immune-related adverse event (irAE) references are also included.

About the Institution: Tung's Taichung MetroHarbour Hospital (童綜合醫院), a medical corporation located in central Taiwan, has approximately 1,200 beds. Established in Shalu, Taichung City in 1971, the hospital has provided over 47 years of distinguished medical services. Committed to continuous improvement, the hospital has continually invested in the latest medical technologies and equipment to provide patients with the highest quality of treatment and care.

Medical Supporter, affiliated with Shingihou Co., Ltd. in Japan, assists clients with clinical trial consultations in Taiwan and Japan. For further information about this bladder cancer clinical trial, please contact us through our official channels.

Official website: https://www.medicalsupporter.org

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-409-5655
Formerly officially certified, No. B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

Figure 5Figure 5

Figure 6Figure 6

Figure 7Figure 7

Related Reading